You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Epirubicin

Showing 1 - 25 of 709
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Tumors Trial in Shanghai (Epirubicin, Docetaxel, cyclophosphamide)

Completed
  • Breast Neoplasms
  • Epirubicin
  • +2 more
  • Shanghai, Shanghai, China
    Ruijin Hospital
Oct 26, 2022

Histological or Cytological Confirmed Stage ? and ?a Thymoma Trial in Shanghai (NAB-Paclitaxel plus Cisplatin, Cisplatin plus

Not yet recruiting
  • Histological or Cytological Confirmed Stage Ⅲ and Ⅳa Thymoma
  • NAB-Paclitaxel plus Cisplatin
  • Cisplatin plus Epirubicin plus Cyclophosphamide
  • Shanghai, Shanghai, China
    Yian Zhang
Apr 17, 2023

Bladder Cancer, Epirubicin Adverse Reaction, Superficial Bladder Cancer Trial in Ankara (Intravesical Solution)

Recruiting
  • Bladder Cancer
  • +3 more
  • Intravesical Solution
  • Ankara, Altindag, Turkey
    Ankara Training and Research Hospital
Jul 4, 2022

TNBC - Triple-Negative Breast Cancer Trial (epirubicin,cyclophosphamide,paclitaxel,Carrelizumab,

Not yet recruiting
  • TNBC - Triple-Negative Breast Cancer
  • (no location specified)
May 8, 2023

Breast Cancer, Chemo Effect Trial (Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel, Epirubicin, Cyclophosphamide,

Not yet recruiting
  • Breast Cancer
  • Chemotherapy Effect
  • Epirubicin, Cyclophosphamide, Xihuang Pill, Docetaxel
  • Epirubicin, Cyclophosphamide, Docetaxel
  • (no location specified)
Jun 21, 2023

Stage III Breast Cancer AJCC V7 Trial in Bergen (epirubicin/docetaxel sequential)

Active, not recruiting
  • Stage III Breast Cancer AJCC V7
  • epirubicin/docetaxel sequential
  • Bergen, Norway
    Dept of Oncology
Jun 24, 2022

Hormone Receptor Positive HER-2 Negative Breast Cancer Trial in Shanghai (Docetaxel, Carboplatin, Epirubicin)

Recruiting
  • Hormone Receptor Positive HER-2 Negative Breast Cancer
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Jun 12, 2023

Non-muscle Invasive Bladder Cancer Trial in Shanghai (APL-1202 in combination with Epirubicin, Placebo in combination with

Active, not recruiting
  • Non-muscle Invasive Bladder Cancer
  • APL-1202 in combination with Epirubicin
  • Placebo in combination with Epirubicin
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 21, 2022

Triple-Negative Breast Cancer Trial in Guangzhou (DCb (docetaxel/carboplatin) versus EC followed by D

Completed
  • Triple-Negative Breast Cancer
  • DCb (docetaxel/carboplatin) versus EC followed by D (epirubicin/cyclophosphamide followed by docetaxe)
  • Guangzhou, Guangdong, China
    Guangdong General Hospital
Aug 27, 2022

Soft Tissue Sarcoma Trial in Beijing, Shanghai (Anlotinib HCl capsule, Epirubicin, Arotinib HCl capsule )

Recruiting
  • Soft Tissue Sarcoma
  • Anlotinib hydrochloride capsule
  • +2 more
  • Beijing, Beijing, China
  • +2 more
Feb 16, 2022

Sepsis Trial in Germany (Epirubicin, Placebo)

Not yet recruiting
  • Sepsis
  • Epirubicin
  • Placebo
  • Jena, Thuringia, Germany
  • +4 more
Feb 25, 2022

Localized Breast Cancer Trial in Dijon (Dense dose epirubicin-cyclophosphamide chemo and G-CSF (filgrastim, lenograstim), Dense

Not yet recruiting
  • Localized Breast Cancer
  • Dense dose epirubicin-cyclophosphamide chemotherapy and G-CSF (filgrastim, lenograstim)
  • Dense dose epirubicin-cyclophosphamide chemotherapy with administration of peg-G-CSF (pegfilgrastim)
  • Dijon, Bourgogne, France
    Centre Georges François Leclerc (CGFL)
Mar 24, 2022

Bladder Cancer Trial in Larissa (Gemcitabine Hydrochloride combined with continuous saline irrigation, Epirubicin Hydrochloride

Recruiting
  • Bladder Cancer
  • Gemcitabine Hydrochloride combined with continuous saline irrigation
  • Epirubicin Hydrochloride combined with continuous saline irrigation
  • Larissa, Larissa/Thessaly, Greece
    Urology Department, University of Thessaly, University Hospital
Jan 25, 2022

Breast Cancer, TNBC - Triple-Negative Breast Cancer Trial (Toripalimab, Epirubicin, High Intensity Focused Ultrasoun)

Not yet recruiting
  • Breast Cancer
  • TNBC - Triple-Negative Breast Cancer
  • (no location specified)
Aug 5, 2022

Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma Trial in Guangzhou (Pyrotinib,

Not yet recruiting
  • Breast Cancer Invasive
  • +3 more
  • Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
  • Placebo, epirubicin or doxorubicin, cyclophosphamide, paclitaxel
  • Guangzhou, Guangdong, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Nov 17, 2023

Leiomyosarcoma Trial in Beijing (Temozolomide for injection combined with epirubicin)

Recruiting
  • Leiomyosarcoma
  • Temozolomide for injection combined with epirubicin
  • Beijing, Beijing, China
    Cancer Hospital of Chinese Academy of Medical Sciences
Jan 11, 2022

Non-muscle Invasive Bladder Cancer Trial in Shanghai (APL-1202, Epirubicin Hydrochloride)

Recruiting
  • Non-muscle Invasive Bladder Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 21, 2022

Chemotherapy Administration on Skeletal Muscle of Breast Cancer

Recruiting
  • Breast Cancer
  • Strasbourg, France
    Institut de Cancerologie Strasbourg Europe
Mar 29, 2022

Breast Tumors Trial in Guangzhou (Trilaciclib, Epirubicin, Cyclophosphamide)

Not yet recruiting
  • Breast Neoplasms
  • Guangzhou, Gangdong, China
    Sun-yat sen university cancer center
Jul 30, 2023

TNBC - Triple-Negative Breast Cancer Trial in Nanjing (Fluzoparib+Paclitaxel, Epirubicin+Cyclophosphamide)

Recruiting
  • TNBC - Triple-Negative Breast Cancer
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Apr 27, 2023

Hepatocellular Carcinoma Trial in Hangzhou (Idarubicin Hydrochloride for Injection, Epirubicin)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Idarubicin Hydrochloride for Injection
  • Epirubicin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Sep 13, 2021

Breast Cancer Trial in Hangzhou (Docetaxel, Carboplatin, Trastuzumab)

Recruiting
  • Breast Cancer
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jun 28, 2022

Breast Cancer Trial in Hangzhou (Docetaxel, Carboplatin, Trastuzumab)

Recruiting
  • Breast Cancer
  • Hangzhou, Zhejiang, China
    2nd Affiliated Hospital, School of Medicine, Zhejiang University
Jun 28, 2022

Breast Cancer Trial (Gemcitabine, Epirubicin, Docetaxel)

Completed
Has Results
  • Breast Cancer
  • (no location specified)
Oct 4, 2021

HER2-negative Early Breast Cancer Trial in Beijing (neoadjuvant chemo upon in vitro PTC drug sensitivity screening for triple

Recruiting
  • HER2-negative Early Breast Cancer
  • neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer
  • neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
  • Beijing, China
    Peking University People's Hospital
Mar 27, 2022